JNJ vs REGN
By Alex · Tickerpine
Johnson & Johnson vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | REGN |
|---|---|---|
| Price | $260.86 | $797.99 |
| Market cap | $628.65B | $82.16B |
| P/E ratio | 30.3 | 19.7 |
| ROE | 25.74% | 14.04% |
| Profit margin | 21.48% | 27.87% |
| Revenue growth | 6.60% | 16.70% |
| Dividend yield | 2.05% | 0.47% |
| Beta | 0.23 | 0.19 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs REGN in plain English
- JNJ is the bigger company — about 7.7× the market cap of REGN.
- REGN is cheaper on earnings (P/E 19.7 vs 30.3).
- JNJ earns a higher return on equity (26% vs 14%).
- REGN is growing revenue faster (17% vs 7%).
- JNJ has the higher dividend yield (2.05% vs 0.47%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.